Arovella Therapeutics Ltd Total Liabilities
Arovella Therapeutics Ltd total liabilities. Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has total liabilities worth AU$1.33 Million AUD (≈ $940.32K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Arovella Therapeutics Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Arovella Therapeutics Ltd (2001–2025)
Total liabilities of Arovella Therapeutics Ltd from 2001 to 2025. This chart illustrates how Arovella Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Arovella Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Arovella Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elastron S.A. - Steel Service Centers
AT:ELSTR
|
Greece | €115.39 Million |
|
Dimension Computer Technology Co Ltd
TWO:6140
|
Taiwan | NT$940.09 Million |
|
Altustfi
WAR:ALI
|
Poland | zł20.07 Million |
|
Apollo Minerals Ltd
AU:AON
|
Australia | AU$784.61K |
|
Greatland Resources Limited
LSE:GGP
|
UK | GBX371.74 Million |
|
Unifosa
TWO:8277
|
Taiwan | NT$30.92 Million |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT3
|
Germany | €74.35 Million |
|
Entertainment Network (India) Limited
NSE:ENIL
|
India | Rs-7.59 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Arovella Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALA total assets.
Liquidity & Leverage Metrics
Arovella Therapeutics Ltd Total Liabilities Ratios Explained
Arovella Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 15.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arovella Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arovella Therapeutics Ltd (2001–2025)
The table below shows the annual total liabilities of Arovella Therapeutics Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.52 Million ≈ $1.08 Million |
-25.89% |
| 2024-06-30 | AU$2.06 Million ≈ $1.46 Million |
+21.63% |
| 2023-06-30 | AU$1.69 Million ≈ $1.20 Million |
+5.99% |
| 2022-06-30 | AU$1.60 Million ≈ $1.13 Million |
-6.46% |
| 2021-06-30 | AU$1.71 Million ≈ $1.21 Million |
-33.69% |
| 2020-06-30 | AU$2.57 Million ≈ $1.82 Million |
+13.02% |
| 2019-06-30 | AU$2.28 Million ≈ $1.61 Million |
-56.04% |
| 2018-06-30 | AU$5.18 Million ≈ $3.66 Million |
+63.68% |
| 2017-06-30 | AU$3.16 Million ≈ $2.24 Million |
+8.73% |
| 2016-06-30 | AU$2.91 Million ≈ $2.06 Million |
-17.35% |
| 2015-06-30 | AU$3.52 Million ≈ $2.49 Million |
-19.18% |
| 2014-06-30 | AU$4.36 Million ≈ $3.08 Million |
+7.84% |
| 2013-06-30 | AU$4.04 Million ≈ $2.86 Million |
+47.27% |
| 2012-06-30 | AU$2.74 Million ≈ $1.94 Million |
+9.98% |
| 2011-06-30 | AU$2.49 Million ≈ $1.76 Million |
-29.89% |
| 2010-06-30 | AU$3.56 Million ≈ $2.52 Million |
-54.22% |
| 2009-06-30 | AU$7.77 Million ≈ $5.50 Million |
+39.87% |
| 2008-06-30 | AU$5.55 Million ≈ $3.93 Million |
-16.74% |
| 2007-06-30 | AU$6.67 Million ≈ $4.72 Million |
+103.52% |
| 2006-06-30 | AU$3.28 Million ≈ $2.32 Million |
+1.58% |
| 2005-06-30 | AU$3.23 Million ≈ $2.28 Million |
+14.40% |
| 2004-06-30 | AU$2.82 Million ≈ $2.00 Million |
+218.60% |
| 2003-06-30 | AU$885.34K ≈ $626.43K |
+505.38% |
| 2002-06-30 | AU$146.25K ≈ $103.48K |
+3974.81% |
| 2001-06-30 | AU$3.59K ≈ $2.54K |
-- |
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more